Bert Vogelstein awarded Warren Triennial Prize by assachusetts General Hospital

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BERT VOGELSTEIN was awarded the 2014 Warren Triennial Prize by Massachusetts General Hospital.

Vogelstein is the Clayton Professor of Oncology and Pathology and director of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University School of Medicine. The award will be presented at the Warren Triennial Prize Symposium, “The Genetics of Cancer,” on Nov. 24 at MGH.

Vogelstein and his colleagues demonstrated that colorectal tumors result from the gradual accumulation of alterations in specific oncogenes and tumor suppressor genes, with major implications for improved diagnostic and therapeutic strategies.

He and his colleagues were also the first to map cancer genomes and to use genome-wide sequencing to identify the basis of a hereditary disease. His team has determined the genetic landscapes of more than a dozen tumor types.

The Warren Prize is the top scientific award presented by MGH, and includes a cash award of $50,000. Created in 1871, the prize was named for John Collins Warren, a co-founder of the MGH who played a leading role in establishing what became the New England Journal of Medicine, and also performed the first public surgical operation utilizing ether anesthesia in 1846.

Twenty-three Warren recipients have also received the Nobel Prize–including 2011 recipient Shinya Yamanaka, a 2012 Nobel laureate; and 2004 recipients Craig Mello and Andrew Fire, who received the 2006 Nobel.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login